Cooperative Agreement U01FD008041
Award Date
9/15/23
Completion Date
8/31/25
Dollars Obligated
$1.5M
Funding Federal Agency
Center for Drug Evaluation and Research
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Cooperative Agreement
Place of Performance
Virginia, USA
Similar Awards
This $1.5 million cooperative agreement from the Department of Health and Human Services' Food and Drug Administration (FDA) Research program (CFDA 93.103) supports the development and validation of a best practices framework for physiologically-based pharmacokinetic (PBPK) analysis to support model-informed biowaivers of fed bioequivalence studies for Biopharmaceutics Classification System Class II drugs. The University of Florida is the primary awardee. Under the award, the University of...
The U.S. Food and Drug Administration (FDA) awarded a $249,485 Cooperative Agreement under the FDA Research program (CFDA 93.103) to Simulations Plus Inc. The project, titled "From Bench to Bioequivalence: In Vitro Mechanistic Understanding of ASD Drug Products in Simulated Gastrointestinal Conditions," aims to enhance the understanding of how food and gastric pH affect the release of drugs from amorphous solid dispersion (ASD) formulations, and how formulation and manufacturing...
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $298,422 to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to develop a semi-automated surveillance system using tree-based scan statistics to monitor the safety and effectiveness of generic drug-device combinations compared to brand-name reference products. The key objectives are to: 1) rigorously describe the uptake...
The U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) awarded a $700,000 Cooperative Agreement (Grant No. U01FD008451) under the FDA Research program (CFDA 93.103) to Duke University's Duke-Robert J. Margolis, MD, Institute for Health Policy. This 5-year award supports Duke-Margolis in executing collaborative research projects with CDER to explore and address critical public health topics related to FDA's oversight of medical products, policy, and...
This Cooperative Agreement award from the U.S. Food and Drug Administration (FDA) under the Food and Drug Administration Research program (CFDA 93.103) provides $150,000 in funding to the Pharmaceutical Inspection Co-Operation Scheme-Association De Droit Suisse (PIC/S) to develop and implement a web-based educational center for pharmaceutical inspectors worldwide. The key objectives of this project are to: 1) Harmonize and standardize good manufacturing practice (GMP) training and...
This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) supports the finalization of a statistical analysis plan, cross-sectional data analysis, and preparation of a quantitative study report for the Chronic Heart Failure Symptom Scale (CHF-SS). The $249,826 award to the Critical Path Institute (C-Path), a non-profit research organization, aims to obtain the quantitative evidence necessary to qualify the CHF-SS for use in...
This $1,500,000 Cooperative Agreement award from the U.S. Food and Drug Administration (FDA) under CFDA 93.103 "Food and Drug Administration Research" will be used by the World Health Organization (WHO) to strengthen regulatory systems and improve global food and medical product quality and safety. The 60-month project aims to achieve oversight and build capacities for regulatory oversight in WHO member states, generate the required international framework for global coordination of...
This $499,550 Cooperative Agreement awarded by the U.S. Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) aims to identify and address barriers to clinical trial participation experienced by urban American Indians. The project will create a Community Research Worker (CRW) role, similar to a Community Health Worker, to serve as a liaison between the clinical trial services and the urban American Indian community. The CRW will build trusting relationships, assess...
The U.S. Food and Drug Administration (FDA) has awarded a $549,485 Cooperative Agreement under the FDA Research program (CFDA 93.103) to Oklahoma State University (OSU) to develop advanced machine learning (ML) models, known as reduced order models (ROMs), to improve the understanding of variability in generic orally inhaled drug products (OIDPs) and enhance comparability and demonstration of bioequivalence (BE) more efficiently. The key products and services to be delivered under this 2-year...
This $300,000 Cooperative Agreement award, funded by the Food and Drug Administration (FDA) under the Food and Drug Administration Research program (CFDA 93.103), supports research to develop physiologically-based pharmacokinetic (PBPK) model-based mechanistic in vitro-in vivo correlations (IVIVC) for long-acting injectable (LAI) suspension drug products. The project, led by the University of Connecticut, aims to: 1) investigate the relationships between physicochemical properties of...